PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30899391-3	2019	We examined the interactions of metformin and sitagliptin treatment with the JAK2/STAT3 pathway and cardiac remodeling.	Sitagliptin Phosphate	46-57	Janus kinase 2	Rattus norvegicus	77-81	
30899391-11	2019	The superior cardio-protective effect of metformin over sitagliptin treatment may partly account for the differences we observed in JAK2/STAT3 activation, indicating that measuring JAK2/STAT3 pathway coupled with metformin treatment may give insight into a more promising DM treatment.	Sitagliptin Phosphate	56-67	Janus kinase 2	Rattus norvegicus	132-136	
30899391-11	2019	The superior cardio-protective effect of metformin over sitagliptin treatment may partly account for the differences we observed in JAK2/STAT3 activation, indicating that measuring JAK2/STAT3 pathway coupled with metformin treatment may give insight into a more promising DM treatment.	Sitagliptin Phosphate	56-67	Janus kinase 2	Rattus norvegicus	181-185	
29885296-6	2018	Interestingly, sitagliptin pretreatment downregulated the RAGE-JAK2/STAT3 pathway and decreased the expression of CXCL4 and CXCR3.	Sitagliptin Phosphate	15-26	Janus kinase 2	Rattus norvegicus	63-67	
29885296-8	2018	Altogether, our present data suggest that sitagliptin has an anticonvulsant effect, which might act via downregulation of the CXCL4/CXCR3 axis, followed by a decrease in RAGE and JAK2/STAT3 expression.	Sitagliptin Phosphate	42-53	Janus kinase 2	Rattus norvegicus	179-183